STERIS Valuation
Is STE N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of STE N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: STE N (MX$3824.43) is trading above our estimate of fair value (MX$2715.2)
Significantly Below Fair Value: STE N is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STE N?
Key metric: As STE N is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is STE N's PS Ratio? | |
|---|---|
| PS Ratio | 4.4x |
| Sales | US$5.09b |
| Market Cap | US$22.15b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.9x |
| Enterprise Value/EBITDA | 18.5x |
| PEG Ratio | 5.8x |
Price to Sales Ratio vs Peers
How does STE N's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.2x | ||
PODD Insulet | 9.2x | 14.3% | US$18.2b |
SOON Sonova Holding | 5.2x | 6.3% | CHF 18.9b |
DXCM DexCom | 7.5x | 13.3% | US$29.6b |
STMN Straumann Holding | 6.9x | 8.6% | CHF 17.6b |
STE N STERIS | 4.4x | 7.0% | Mex$22.1b |
Price-To-Sales vs Peers: STE N is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (6.6x).
Price to Sales Ratio vs Industry
How does STE N's PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 135 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 135 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: STE N is expensive based on its Price-To-Sales Ratio (4.4x) compared to the Global Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is STE N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate STE N's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Médica Sur. de
Mex$3.1b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$28.84
7D
1.2%
1Y
-31.0%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a